160 related articles for article (PubMed ID: 28976449)
1. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract][Full Text] [Related]
2. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
Hillman RT; Chisholm GB; Lu KH; Futreal PA
J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
Zhang Q; Wang C; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):368-374. PubMed ID: 30448260
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
[TBL] [Abstract][Full Text] [Related]
5. Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.
De Donato M; Petrillo M; Martinelli E; Filippetti F; Zannoni GF; Scambia G; Gallo D
Gynecol Oncol; 2017 Jul; 146(1):170-178. PubMed ID: 28495238
[TBL] [Abstract][Full Text] [Related]
6. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
8. HMGA2 and high-grade serous ovarian carcinoma.
Wu J; Wei JJ
J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
[TBL] [Abstract][Full Text] [Related]
9. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
[TBL] [Abstract][Full Text] [Related]
10. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.
Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B
Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403
[TBL] [Abstract][Full Text] [Related]
11. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
12. KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.
De Donato M; Babini G; Mozzetti S; Buttarelli M; Ciucci A; Arduini G; De Rosa MC; Scambia G; Gallo D
J Exp Clin Cancer Res; 2020 Nov; 39(1):265. PubMed ID: 33250051
[TBL] [Abstract][Full Text] [Related]
13. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
14. High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers.
Miyamoto M; Takano M; Iwaya K; Shinomiya N; Goto T; Kato M; Suzuki A; Aoyama T; Hirata J; Nagaoka I; Tsuda H; Furuya K
Br J Cancer; 2015 Feb; 112(4):739-44. PubMed ID: 25628093
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of nuclear morphometric analysis in serous ovarian carcinoma.
Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Rollason TP
Int J Gynecol Cancer; 2008; 18(4):692-701. PubMed ID: 17944918
[TBL] [Abstract][Full Text] [Related]
16. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
18. Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.
Labrie M; De Araujo LOF; Communal L; Mes-Masson AM; St-Pierre Y
Sci Rep; 2017 Oct; 7(1):13244. PubMed ID: 29038585
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.
Hinchcliff E; Paquette C; Roszik J; Kelting S; Stoler MH; Mok SC; Yeung TL; Zhang Q; Yates M; Peng W; Hwu P; Jazaeri A
Cancer Immunol Immunother; 2019 Sep; 68(9):1515-1526. PubMed ID: 31515669
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic significance of APE1/Ref-1 and NPM1 proteins in high-grade ovarian serous cancer.
Londero AP; Orsaria M; Tell G; Marzinotto S; Capodicasa V; Poletto M; Vascotto C; Sacco C; Mariuzzi L
Am J Clin Pathol; 2014 Mar; 141(3):404-14. PubMed ID: 24515769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]